Statins Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Lipid-Lowering Agents (Statins) DMPK and Bioanalytical Services

Statin DDI risk is not a single-mechanism problem. Lovastatin’s hepatic clearance follows three sequential steps: OATP1B1/3-mediated hepatocellular uptake, CYP3A4-mediated Phase I metabolism, and P-gp-mediated biliary efflux. A co-administered drug that inhibits any one step — whether an OATP inhibitor, a CYP3A4 inhibitor, or a P-gp inhibitor — can produce clinically significant changes in systemic exposure. CYP3A4-only DDI screening captures the metabolic dimension but misses OATP uptake inhibition and P-gp efflux competition entirely.

Creative Proteomics provides statin-focused DMPK workflows spanning OATP1B1/3 transporter uptake studies, CYP3A4 metabolic profiling, P-gp efflux assessment, multi-step pathway-aware DDI risk profiling, and custom statin panel development.

Browse Drug Index Request Custom Statin Method Support

OATP1B1/3 Uptake: The Overlooked DDI GatewayLovastatin enters hepatocytes via OATP1B1/3. OATP inhibitors block entry — a DDI mechanism missed by CYP-only screening.

CYP3A4 Metabolism + P-gp EffluxAfter uptake, CYP3A4 metabolizes lovastatin; P-gp pumps parent and metabolites into bile. Either step inhibited → exposure amplified.

Three-Step Pathway, Three DDI VulnerabilitiesOATP uptake + CYP3A4 metabolism + P-gp efflux = three independent DDI target sites on one clearance pathway.

Statin Three-Step DDI Risks DMPK Strategy Map

⚡

Step 1: OATP1B1/3 Hepatocellular UptakeLovastatin enters hepatocytes via OATP1B1/3 transporters. OATP inhibitors (cyclosporine, rifampicin) block uptake — missed by CYP-only DDI screens.

🧬

Step 2: CYP3A4 Phase I MetabolismOnce intracellular, CYP3A4 metabolizes lovastatin. CYP3A4 inhibitors (ketoconazole, itraconazole) act at this step — the dimension captured by standard DDI screens.

📊

Step 3: P-gp Biliary EffluxParent lovastatin and metabolites are excreted into bile via P-gp. P-gp inhibition reduces biliary clearance and increases intracellular exposure.

🔬

Integrated Three-Step DDI ProfileA complete lovastatin DDI assessment requires OATP uptake, CYP3A4 inhibition, and P-gp efflux arms — three mechanisms, one compound.

Statin three-step DDI pathway triage.Creative Proteomics maps OATP1B1/3 uptake, CYP3A4 metabolism, and P-gp efflux as three independent DDI dimensions — because CYP3A4-only screening answers one-third of the lovastatin DDI question.

Statin Drug Index

Find the Statin Compound Behind the Study

Statin DDI studies require attention to the full hepatic clearance pathway: OATP1B1/3-mediated uptake, CYP3A4 metabolism, and P-gp efflux — three sequential steps that each represent an independent DDI vulnerability. The drug panel is intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only statins matching all selected values.

1 entry · Page 1 of 1

Analytical Pain Points

What Drives Assay Failure in Statin DDI Studies?

Lovastatin DDI risk is defined by its clearance pathway geometry — three sequential steps, any one of which can be inhibited by a co-administered drug. CYP-only screening sees one step; the other two remain invisible until the interaction manifests in vivo.

OATP1B1/3 Uptake Inhibition Is Missed by CYP-Only Screens

Lovastatin enters hepatocytes via OATP1B1/3. Cyclosporine, rifampicin, and other OATP inhibitors block this uptake step, increasing systemic exposure. Standard CYP3A4 DDI panels — β-NADPH-supplemented microsomes — have no OATP transporters and will not detect this mechanism.

Our responseOATP1B1/3-expressing hepatocyte uptake assays with known OATP inhibitor controls to quantify uptake-mediated DDI contribution.

Transporter Interaction Bioanalysis →

CYP3A4 Metabolism: The Classical DDI Target

Once inside the hepatocyte, CYP3A4 metabolizes lovastatin via Phase I oxidation. This is the step captured by standard DDI screens — but it is only one-third of the clearance pathway. CYP3A4 inhibitors (ketoconazole, itraconazole) produce DDI through this dimension.

Our responseCYP3A4 isoform-specific inhibition assays with IC₅₀ determination and time-dependent inhibition assessment for lovastatin.

CYP Inhibition Assays →

P-gp Efflux Competition: The Third DDI Vulnerability

After metabolism, parent lovastatin and its metabolites are excreted into bile via P-gp. P-gp inhibitors reduce biliary clearance and increase intracellular and systemic exposure — a DDI mechanism distinct from both OATP uptake inhibition and CYP3A4 metabolism inhibition.

Our responseP-gp substrate classification and efflux inhibition studies to assess P-gp-mediated DDI contribution independently of CYP3A4 and OATP.

DDI Screening Services →

Microsomes vs Hepatocytes: Transporters Need Intact Cells

CYP3A4 exists in both microsomes and hepatocytes. OATP1B1/3 and P-gp exist only in intact hepatocytes. A microsome-only DDI study quantifies CYP3A4 inhibition accurately but contributes zero data on OATP or P-gp interactions — producing an incomplete DDI risk profile.

Our responseHepatocyte-based DDI workflows with intact transporter function for OATP uptake and P-gp efflux, combined with microsome-based CYP3A4 inhibition for complete three-step DDI mapping.

Custom LC-MS/MS Method Development →

Integrated Three-Step DDI Study Design

A complete lovastatin DDI assessment requires three parallel experiments: OATP1B1/3 uptake inhibition in hepatocytes, CYP3A4 inhibition in microsomes, and P-gp efflux inhibition in polarized hepatocyte or vesicle models — three mechanisms, one compound, with data integration that standard single-mechanism screens do not provide.

Our responseIntegrated three-step statin DDI panels with OATP uptake, CYP3A4 inhibition, and P-gp efflux arms combined into a single lovastatin DDI risk profile.

Custom Panels →

Focused Service Paths

Four Practical Routes for Statin DDI Studies

Statin DDI workflows should address each clearance step independently: OATP1B1/3 uptake studies for entry-phase DDI, CYP3A4 inhibition assays for metabolic DDI, P-gp efflux studies for biliary clearance DDI, or integrated panels covering all three steps in one study design.

OATP1B1/3 Transporter Uptake Studies

OATP1B1/3-mediated hepatocellular uptake of lovastatin with known inhibitor controls to quantify uptake-phase DDI contribution.

OATP1B1/3-expressing hepatocyte models
Uptake inhibition with cyclosporine / rifampicin controls
Uptake clearance rate determination

Transporter Interaction Bioanalysis →

CYP3A4 Metabolic DDI Profiling

CYP3A4 isoform-specific inhibition and time-dependent inhibition assays with IC₅₀ determination for lovastatin.

CYP3A4 inhibition IC₅₀ determination
Time-dependent inhibition (TDI) assessment
Substrate depletion kinetics

CYP Inhibition Assays →

P-gp Efflux Transporter Assessment

P-gp substrate classification and efflux inhibition studies for lovastatin and metabolites.

P-gp substrate verification
Efflux inhibition with P-gp inhibitor controls
Biliary clearance contribution modeling

DDI Screening Services →

Integrated Three-Step Statin DDI Panel

Three-step OATP-CYP3A4-P-gp DDI panel with hepatocyte uptake, microsome CYP3A4 inhibition, and P-gp efflux arms in one lovastatin study.

OATP1B1/3 uptake arm
CYP3A4 inhibition arm
P-gp efflux arm
Integrated three-step DDI risk profile

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need DDI Support for Lovastatin or Another Statin?

If your statin study requires OATP uptake, CYP3A4 metabolism, and P-gp efflux profiling across a compound’s full hepatic clearance pathway, standard single-mechanism DDI screens may produce an incomplete risk profile.

Creative Proteomics designs statin DDI workflows by defining OATP1B1/3 uptake status, CYP3A4 metabolic profile, P-gp efflux relevance, biological system (hepatocyte vs microsome), and the scope — single-step or integrated three-step — before method development.

Target statin

OATP1B1/3 uptake status

CYP3A4 inhibition need

P-gp efflux status

Three-step integrated or single-step

Panel requirements